IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v22y2025i4p509-d1621516.html
   My bibliography  Save this article

Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe

Author

Listed:
  • Blessing Dzingirai

    (Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
    Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare P.O. Box MP 167, Zimbabwe)

  • Leolin Katsidzira

    (Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare P.O. Box MP 167, Zimbabwe)

  • Maarten J. Postma

    (Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands)

  • Marinus van Hulst

    (Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
    Department of Clinical Pharmacy and Toxicology, Martini Hospital, 9728 NL Groningen, The Netherlands)

  • Nyashadzaishe Mafirakureva

    (Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2TN, UK)

Abstract

Background: The aim of this study was to assess the cost effectiveness of a screening and treatment intervention approach for chronic HCV infection in Zimbabwe. Methods: Using a decision tree and a validated Markov model, we estimated the lifetime costs and health effects of screening for and treating HCV infections from a healthcare perspective. We evaluated three screening strategies, namely the following: i. no screening; ii. screening among the general population; and iii. screening among high-risk groups. Incremental cost effectiveness ratios were calculated for the strategies that were not dominated. We used deterministic and probabilistic sensitivity analyses to explore the impacts of parameter uncertainty on cost effectiveness outcomes. Results: The strategy of screening among high-risk groups and treating with sofosbuvir/velpatasvir had an incremental cost of USD 1201 and incremental quality-adjusted life years (QALY) of 2.01, yielding an incremental cost effectiveness ratio (ICER) of USD 604 per QALY gained as compared to no screening. The ICER was below the 0.5 times the gross domestic product per capita parameter (USD 796), making the intervention potentially cost effective. The strategy to screen among the general population was dominated, because it costed more and resulted in fewer QALYs than its comparators. Conclusions: Screening for HCV among high-risk populations followed by treatment using sofosbuvir/velpatasvir is cost effective under the assumptions made in this study.

Suggested Citation

  • Blessing Dzingirai & Leolin Katsidzira & Maarten J. Postma & Marinus van Hulst & Nyashadzaishe Mafirakureva, 2025. "Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe," IJERPH, MDPI, vol. 22(4), pages 1-15, March.
    • Handle: RePEc:gam:jijerp:v:22:y:2025:i:4:p:509-:d:1621516
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/22/4/509/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/22/4/509/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:22:y:2025:i:4:p:509-:d:1621516. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.